Comparative Pharmacology
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus NUTRESTORE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus NUTRESTORE.
NORGESTIMATE AND ETHINYL ESTRADIOL vs NUTRESTORE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via estrogen receptor; norgestimate is a progestin that inhibits ovulation and thickens cervical mucus.
NUTRESTORE is a medical food containing L-citrulline, L-ornithine, and other amino acids; its mechanism is not fully characterized but is hypothesized to enhance the urea cycle and reduce ammonia levels by providing substrates for ureagenesis, thereby improving nitrogen disposal in patients with urea cycle disorders or hyperammonemia.
One tablet (norgestimate 0.250 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days followed by 7 placebo tablets.
One capsule (500 mg) orally three times daily.
None Documented
None Documented
Norgestimate: ~21.3 hours (range 16-36 hours); active metabolite 17-deacetyl norgestimate: ~33.2 hours (range 22-45 hours). Ethinyl estradiol: ~17.1 hours (range 14-22 hours). Terminal half-life supports once-daily dosing; steady-state achieved within 10-14 days.
Terminal elimination half-life: 18-24 hours. Steady-state reached after 4-5 days. Clinical context: Allows once-daily dosing; prolonged in renal impairment.
Urine (primarily as glucuronide and sulfate conjugates; ~50-60% of dose), feces (~30-40% of dose as metabolites), minimal unchanged drug in urine
Renal: 50-70% unchanged; biliary/fecal: 20-30% as metabolites; 5-10% in feces as parent drug.
Category D/X
Category C
Estrogen
Estrogen